Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis

Journal of Dermatological Treatment

Volumn 18, Issue 3, 2007, Pages 151-157

  Fleischer Jr , Alan B ^a,e   Abramovits, William ^b   Breneman, Debra ^c   Jaracz, Eileen ^d  

^a WAKE FOREST UNIVERSITY   (United States)

^b Dermatology Treatment and Research Center   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic dermatitis; Pimecrolimus; Tacrolimus; Topical calcineurin inhibitor

Indexed keywords

PIMECROLIMUS; TACROLIMUS;

ADULT; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; BURNING SENSATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HERPES SIMPLEX; HUMAN; IMPETIGO; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION;

ADMINISTRATION, CUTANEOUS; ADULT; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; OINTMENTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; UNITED STATES;

EID: 34249813723     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701287332     Document Type: Article

References (25)

1. Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatol Online J. 2003 Mar;9(2):1.
2. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S118-27.
3. Rudikoff D, Lebwohl D. Atopic dermatitis. Lancet. 1998;351:1715-21.
4. Ellis C, Luger T on behalf of the ICCAD II faculty. International Consensus Conference on Atopic Dermatitis II (ICCAD II): Clinical update and current treatment strategies. Br J Dermatol. 2003;148(suppl 63):3-10.
5. Herd RM, Tidman MJ, Prescott RJ, Hunter JA. Prevalence of atopic eczema in the community: The Lothian atopic dermatitis study. Br J Dermatol. 1996 Jul;135:18-9.
6. Hoare C, Li Wan Po A, Williams H. Systemic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1-191.
7. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E, Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, Efficacy. J Am Acad Dermatol. 2001;44(suppl):S28-38.
8. Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I, Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safety. J Am Acad Dermatol. 2001;44(suppl):S39-46.
9. Paller A, Eichenfield LF, Leung DYM, Stewart D, Appell M, and the Tacrolimus Ointment Study Group. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44 (suppl):S47-57.
10. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM, and the Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol. 2001;44(suppl):S58-64.
11. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;136:999-1006.
12. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RGB, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504.
13. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. for the Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2.
14. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M, for the CASM-DE-01 Study Group. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology. 2002;205:271-7.
15. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144:788-94.
16. Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, et al. Long-term (up to 4 years) efficacy and safety of tacrolimus ointment in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53:S186-94.
17. Koo JYM, Fleischer AB Jr, Abramovits W, Pariser DM, McCall CO, Horn T, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: Results in 8000 patients. J Am Acad Dermatol. 2005;53:S195-205.
18. Luger J, Lahfa M, Fölster-Holst R, Gulliver WP, Allen R, Molloy S, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15:169-78.
19. Paller AS, Lebwohl M, Fleischer AB, Antaya R, Langley RG, Kirsner AS, et al. for the US/Canada Tacrolimus Ointment Study Group. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52:810-22.
20. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44-7.
21. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, GraeberM, et al. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11-18.
22. Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150:96-102.
23. Lübbe J, Friedlander SF, Cribier B, Morren M-A, Garcia-Rodriguez A, Gelmetti C, et al. on behalf of the NOBEL (New Online Based ELidel) Study Group. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7:121-31.
24. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51:515-25.
25. Bigby M. Tacrolimus and pimecrolimus for atopic dermatitis. Where do they fit in? Arch Dermatol. 2006;142: 1203-5.